Loophole in Patent Law Brings ‘Miracle Drug’ to Patients Who Can’t Afford It

Beximco Pharma has begun distributing a generic version of a cystic fibrosis treatment, branded as TRIKO, to patients in six countries. This initiative provides a lower-cost alternative for individuals unable to access existing, higher-priced therapies. The distribution is characterized as a response to specific gaps within current patent law regulations.

Coverage from The New York Times, TipRanks, Newagebd.net, The Business Standard, and daily-sun.com highlights the drug's affordability and the legal mechanism enabling its release. Reports emphasize that the first patients have already received the therapy, marking the start of the supply program. Future developments will depend on the continued availability of the medication and any potential regulatory or legal responses regarding the use of the patent loophole.

Coverage does not yet specify which countries are included in the distribution or the long-term impact on global access to the therapy.